S. L. Gwaltney

发表

Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors.

Chang Park, Saul H Rosenberg, Gaoquan Li, 2006, Bioorganic & medicinal chemistry letters.

Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.

S. L. Gwaltney, Lihong Shi, R. Skene, 2012, Bioorganic & medicinal chemistry letters.

Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.

D. Kassel, S. L. Gwaltney, Lihong Shi, 2008, Bioorganic & medicinal chemistry letters.

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

D. Kassel, S. L. Gwaltney, K. Aertgeerts, 2011, Journal of medicinal chemistry.

Bridged to fused ring interchange. The total synthesis of (±)-ledol

S. L. Gwaltney, K. Shea, 1996 .

Bridged to fused ring interchange. New methodology for the construction of fused cycloheptanes and cyclooctanes

S. L. Gwaltney, K. Shea, S. Sakata, 1995 .

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

C. Johnson, S. Almo, Lan Hua, 2017, ACS medicinal chemistry letters.

Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative.

S. Ng, S. Rosenberg, S. L. Gwaltney, 2003, Molecular cancer therapeutics.

Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases.

S. L. Gwaltney, J. McKerrow, W. Roush, 1999 .

Novel sulfonate derivatives: potent antimitotic agents.

S. Ng, P. Kovar, S. L. Gwaltney, 2001, Bioorganic & medicinal chemistry letters.

Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine Proteases

S. L. Gwaltney, J. McKerrow, W. Roush, 1998 .

Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.

S. Ng, P. Kovar, S. Rosenberg, 2002, Bioorganic & medicinal chemistry letters.

Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.

Haiying Zhang, S. Rosenberg, N. Lin, 2003, Bioorganic & medicinal chemistry letters.

New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models.

S. Rosenberg, S. L. Gwaltney, R. B. Credo, 2001, Journal of medicinal chemistry.

Stereoselective synthesis of an advanced taxusin intermediate: an application of the type 2 intramolecular Diels–Alder reaction

S. L. Gwaltney, K. Shea, Markian M Stec, 2003 .

Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.

V. Stoll, S. Muchmore, S. Ng, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.

V. Stoll, S. Rosenberg, Gary T. Wang, 2004, Bioorganic & medicinal chemistry letters.

Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.

S. Ng, P. Kovar, S. L. Gwaltney, 2001, Bioorganic & medicinal chemistry letters.

Inhibitors of Dipeptidyl Peptidase 4

S. L. Gwaltney, J. Stafford, Jeffrey A. Stafford, 2005 .

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.

S. L. Gwaltney, 2008, Current topics in medicinal chemistry.

Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense.

M. Bogyo, S. L. Gwaltney, J. McKerrow, 2001, Molecular and biochemical parasitology.

Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.

Chang Park, Saul H Rosenberg, Y. Tong, 2007, Bioorganic & medicinal chemistry.

Design, synthesis and SAR of novel glucokinase activators.

S. L. Gwaltney, D. Hosfield, Bumsup Lee, 2013, Bioorganic & medicinal chemistry letters.

Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators.

S. L. Gwaltney, D. Hosfield, Bumsup Lee, 2017, Bioorganic & Medicinal Chemistry Letters.

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

D. Kassel, S. L. Gwaltney, K. Takeuchi, 2007, Journal of medicinal chemistry.